Filing Details

Accession Number:
0001549595-24-000105
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-07-30 19:06:11
Reporting Period:
2024-07-30
Accepted Time:
2024-07-30 19:06:11
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1549595 Nurix Therapeutics Inc. NRIX Pharmaceutical Preparations (2834) 270838048
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1817199 Christine Ring C/O Nurix Therapeutics, Inc.
1700 Owens Street, Suite 205
San Francisco CA 94158
Chief Legal Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-07-30 1,924 $0.00 21,762 No 4 M Direct
Common Stock Acquisiton 2024-07-30 2,000 $0.00 23,762 No 4 M Direct
Common Stock Acquisiton 2024-07-30 3,750 $0.00 27,512 No 4 M Direct
Common Stock Disposition 2024-07-30 2,920 $20.67 24,592 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2024-07-30 1,924 $0.00 1,924 $0.00
Common Stock Restricted Stock Units Disposition 2024-07-30 2,000 $0.00 2,000 $0.00
Common Stock Restricted Stock Units Disposition 2024-07-30 3,750 $0.00 3,750 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
11,545 No 4 M Direct
14,000 No 4 M Direct
41,250 No 4 M Direct
Footnotes
  1. The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
  2. Represents the weighted average sale price. The lowest price at which shares were sold was $20.48 and the highest price at which shares were sold was $20.96. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
  3. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
  4. The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.
  5. RSUs do not expire; they either vest or are canceled prior to the vest date.
  6. The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
  7. The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.